PEAChY-M Pharmacological Emergency management of Agitation in Children and Young people: a randomised controlled trial of intraMuscular medication
PEAChY-M Pharmacological Emergency management of Agitation in Children and Young people: a randomised controlled trial of the effectiveness of intraMuscular (IM) medication for the management of acute severe behavioural disturbance.
Murdoch Children's Research Institute (MCRI)
348 participants
Oct 25, 2021
Interventional
Conditions
Summary
Acute severe behavioural disturbance (ASBD) is an emergency situation where a patient experiences severe agitation or aggression. One of the common strategies used to manage those presenting to the emergency department (ED) with ASBD is the provision of medications. Medications assist in allowing the young person to gain control over their behaviour. In most instances, oral medications are used. For a small proportion of young people with ASBD, their emotional dysregulation is so extreme that they are unable or unwilling to accept oral medication and, therefore, IM medication is required to de-escalate their behaviour. In individuals less than 18 years of age, there is no evidence available to guide doctors about which medications are the most effective, despite them being commonly used to manage ASBD. It is also not known how well these medications are tolerated by young people. Therefore, the primary aim of this study is to determine whether, in children and adolescents with ASBD, IM olanzapine is more effective than IM droperidol at achieving successful sedation (i.e.: a state of calm) at 1 hour after randomisation. These medications were chosen as they are the two of the most commonly used medications in Australia. This study will be a randomised, open label, multi-centre effectiveness trial which will enrol young people aged 9 to 17 and 364 days presenting to participating EDs with ASBD. We hope to determine which medication is most effective and to assess the side effects of these medications. We hypothesise that 15% more children will achieve successful sedation 1 hour after randomisation to olanzapine compared to those children who were randomised to droperidol.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
PEAChY-M is a randomised controlled trial which will compare the effectiveness of intramuscular (IM) olanzapine [arm one] to IM droperidol [arm two] for the management of paediatric acute severe behavioural disturbance occurring in the emergency department (ED). ASBD will be determined by confirming the participant has a Sedation Assessment Tool (SAT) score of +1 or greater. Dosing will be based on weight. This is an open label study. The trial medication will be provided by the clinical staff caring for the participant in the ED. Only one dose will be provided as part of the PEAChY-M study. No modifications to the doses or the medications provided will be allowed. Arm One: Participants will receive 5mg IM olanzapine if they weigh <40kg or 10mg if they weigh 40kg or greater.
Locations(10)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12621001238864